RedHill Biopharma Ltd. (NSDQ:RDHL) has randomized the last patient in Part A of an ongoing Phase 2/3 study focused on RHB-107 (upamostat), an investigational antiviral. The Tel Aviv–based company anticipates that RHB-107, a serine protease inhibitor, would be broadly effective against emerging SARS-CoV-2 variants. RedHill Biopharma expects top-line data for Part A of the trial,…
RedHill Biopharma announces positive data for oral COVID-19 drug
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced positive results from a Phase 2 U.S. study involving its opaganib in hospitalized COVID-19 patients with pneumonia. The study indicated that opaganib reduced the need for supplemental oxygen therapy and an earlier hospital discharge. RedHill also concluded that the drug was well-tolerated based on the placebo-controlled Phase 2 study,…
Why RedHill Biopharma is expanding its focus on infectious disease
The specialty biopharmaceutical company Redhill Biopharma (NSDQ:RDHL) recently announced that the first patient had been dosed in a Phase 2/3 investigating the potential of RHB-107 (upamostat) for mild-to-moderate COVID-19. The company is also testing the potential of a drug known as opaganib for hospitalized patients. In the following interview, Gilead Raday, COO at Redhill Biopharma,…